Methodology

All entries for: Sanegene Bio USA Inc.

October 16, 2025

Sanegene Bio USA Inc.

Orphan Drug Designation

FDA orphan drug designation: treatment of complement 3 glomerulopathy

Disease Area: Rare Diseases